HEADACHE, there is still technology risk, but it's just not nearly as big as it was before the Abbott deal. We have no idea what Abbott found during the blind sample verification process. It could have been mediocre for all we know, but if you closely study the website of Abbott Diagnostics you will realize that they BY NO MEANS are cutting deals every day with small biotechs. They seem to be quite careful and picky in their deal-making, which is a good sign for us.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.